Tony S K Mok

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)

S. Lim, Q. Ou, T. Reungwetwattana, 2023, Cancers.

A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score

Q. Miao, Xiaobin Zheng, Longfeng Zhang, 2024, MedComm.

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

J. Gainor, K. Ichikado, J. Sylvester, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

P. Jänne, K. O'Byrne, T. Mok, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Haem oxygenase-1 plays a central role in NNK-mediated lung carcinogenesis

M. Underwood, Ming Li, T. Mok, 2008, European Respiratory Journal.

Breast cancer, early stage

M. Espié, C. Mermel, R. Gelber, 2012 .